AE Management of IO/TKI and Future of nccRCC
Medical experts discuss significant adverse effects of TKIs and IOs, including management and patient education, and highlight exciting pipeline therapies for non–clear cell RCC, such as Ipi + Nivo and zanzalintinib + Nivo.
EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell
EP: 2.Challenges in Treating RCC From Community and Academic Settings
EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates (insert the slide for case in this segment)
EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice
EP: 5.nccRCC: Alternative Therapies
EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC
EP: 7.AE Management of IO/TKI and Future of nccRCC
EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy
EP: 9.NCCN Guideline Updates in Clear-Cell RCC
EP: 10.Best Treatment Selection in Clear-Cell RCC
Video content above is prompted by the following:
- What are the most significant adverse effects seen with TKIs and IOs?
- How do you manage, monitor, and mitigate AEs seen with TKIs/IOS?
What education do you provide patients to ensure they understand their recommended treatment regimens and potential adverse effects with of these frontline agents?
- What pipeline therapies are you most excited about for the treatment of nccRCC?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
